4.6 Article

Up-regulation of microRNA-210 inhibits proliferation of hepatocellular carcinoma cells by targeting YES1

Journal

WORLD JOURNAL OF GASTROENTEROLOGY
Volume 21, Issue 46, Pages 13030-13041

Publisher

BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v21.i46.13030

Keywords

MicroRNA-210; Hepatocellular carcinoma; Proliferation; Yes1

Funding

  1. Biomedical Research Council
  2. Ministry of Education

Ask authors/readers for more resources

AIM: To determine the expression of microRNA-210 (miR-210) in hepatocellular carcinoma (HCC) and to examine its role using HCC cells. METHODS: The expression of miR-210 was determined in 21 pairs of HCC samples and the corresponding surrounding non-tumor tissues. The effects of miR-210 on proliferation and cell cycle progression were examined using HepG2 and HuH7 cells. Overexpression and inhibition of miR-210 was achieved by transfection of the cells with miR-210 mimic or inhibitor. Luciferase reporter constructs were used to identify the miR-210 interacting site on Yes1. Yes1 expression was examined after miR-210 transfection, as well as in the HCC samples. RESULTS: miR-210 was significantly up-regulated by 3.4 fold (P < 0.01) in the tumor samples. The over-expression of miR-210 significantly reduced cell proliferation compared to the mock-treated cells (68.9% +/- 7.4% and 53.6% +/- 5.0%, P < 0.05 for the HepG2 and HuH7 cells respectively). Analysis of the HuH7 cells transfected with miR-210 mimic by flow cytometry showed that the cells took a longer time to reach the G2/M phase. The interaction between miR-210 and the 3'UTR of the Yes1 transcript was confirmed using a luciferase reporter assay. Over-expression of miR-210 reduced the expression of Yes1 protein in both HuH7 and HepG2 cells. Tumors with a greater than fourfold increase in the expression of miR-210 showed consistently lower expressions of Yes1 in the tumors. In nocodazole-treated cells with a significant G2/M cell population, Yes1 protein was significantly reduced and pre-inhibition of miR-210 in HuH7 cells was able to prevent the reduction of Yes1 protein expression. Knock-down of Yes1 by siRNA also led to reduced cell proliferation (70.8% +/- 7.5%, P < 0.05 in the HuH7 cells). CONCLUSION: Up-regulation of miR-210 inhibits cell proliferation. Yes1 is a target of miR-210 and affects cell proliferation in HCC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Phosphoproteomics Unravel HBV Triggered Rewiring of Host Phosphosignaling Events

ZiJie Lim, Nur Khairiah Binte Mohd-Ismail, Evelyn Png, Ching Wooen Sze, Qifeng Lin, Wanjin Hong, Seng Gee Lim, Yee-Joo Tan, Jayantha Gunaratne

Summary: This study investigated the molecular signaling events during early phases of HBV infection by profiling the phosphoproteome of infected cells. The results showed that HBV infection significantly altered the host phosphoproteome and its associated proteins, including kinases. Computational analysis revealed dysregulation of immune response, cell cycle, and RNA processing pathways during HBV infection. Inhibition of CLKs was found to reduce HBV infection. These findings provide potential targets for developing novel therapeutic strategies for HBV treatment.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Letter Gastroenterology & Hepatology

Global multi-stakeholder endorsement of the MAFLD definition

Nahum Mendez-Sanchez, Elisabetta Bugianesi, Robert G. Gish, Frank Lammert, Herbert Tilg, Mindie H. Nguyen, Shiv K. Sarin, Nuria Fabrellas, Shira Zelber-Sagi, Jian-Gao Fan, Gamal Shiha, Giovanni Targher, Ming-Hua Zheng, Wah-Kheong Chan, Shlomo Vinker, Takumi Kawaguchi, Laurent Castera, Yusuf Yilmaz, Marko Korenjak, C. Wendy Spearman, Mehmet Ungan, Melissa Palmer, Mortada El-Shabrawi, Hans-Juergen Gruss, Jean-Francois Dufour, Anil Dhawan, Heiner Wedemeyer, Jacob George, Luca Valenti, Yasser Fouad, Manuel Romero-Gomez, Mohammed Eslam

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Article Gastroenterology & Hepatology

Acute variceal bleeding portends poor outcomes in patients with acute-on-chronic liver failure: a propensity score matched study from the APASL ACLF Research Consortium (AARC)

Sanchit Sharma, Samagra Agarwal, Anoop Saraya, Ashok Choudhury, Mamun Al Mahtab, Mohd Shahinul Alam, Sanjiv Saigal, Dong Joon Kim, C. E. Eapen, Ashish Goel, Qin Ning, Harshad Devarbhavi, Virendra Singh, Akash Shukla, Saeed Hamid, Jinhua Hu, Soek-Siam Tan, Anil Arora, Manoj Kumar Sahu, Mohd Rela, Dinesh Jothimani, P. N. Rao, Anand Kulkarni, Hashmik Ghaznian, Guan Huei Lee, Duan Zhongping, Ajit Sood, Omesh Goyal, Laurentius A. Lesmana, Rinaldi C. Lesmana, Sombat Treeprasertsuk, Nan Yuemin, Samir Shah, Han Tao, V. M. Dayal, Xin Shaojie, Fazal Karim, Zaigham Abbas, Jose D. Sollano, Kemal Fariz Kalista, Ananta Shreshtha, Diana Payawal, Masao Omata, Shiv Kumar Sarin

Summary: This study evaluated the outcomes of acute variceal bleeding (AVB) in patients with acute-on-chronic liver failure (ACLF) and found that patients with AVB had a higher mortality rate.

HEPATOLOGY INTERNATIONAL (2022)

Article Gastroenterology & Hepatology

Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy

Man-Fung Yuen, Jeong Heo, Hiromitsu Kumada, Fumitaka Suzuki, Yoshiyuki Suzuki, Qing Xie, Jidong Jia, Yoshiyasu Karino, Jinlin Hou, Kazuaki Chayama, Michio Imamura, Judy Y. Lao-Tan, Seng Gee Lim, Yasuhito Tanaka, Wen Xie, Jung-Hwan Yoon, Zhongping Duan, Masayuki Kurosaki, Sung-Jae Park, Madalinee Eternity Labio, Rajneesh Kumar, Young-Oh Kweon, Hyung Joon Yim, Yu Tao, Jennifer Cremer, Robert Elston, Matt Davies, Sharon Baptiste-Brown, Kelong Han, Fiona M. Campbell, Melanie Paff, Dickens Theodore

Summary: This study evaluated the safety and efficacy of GSK3389404, a drug targeting chronic HBV infection. The results showed that GSK3389404 can reduce the production of HBV viral proteins, although no optimal dosing regimen was identified.

JOURNAL OF HEPATOLOGY (2022)

Review Gastroenterology & Hepatology

Future anti-HDV treatment strategies, including those aimed at HBV functional cure

Yong Chuan Tan, Guan Huei Lee, Daniel Q. Huang, Seng Gee Lim

Summary: HDV uses the HBV surface antigen to enter hepatocytes and is associated with accelerated fibrosis progression and increased risk of hepatocellular carcinoma. Current HBV antiviral agents have poor activity against HDV, therefore the search for drugs that can cure both HBV and HDV is needed.

LIVER INTERNATIONAL (2023)

Article Gastroenterology & Hepatology

Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort

Yao-Chun Hsu, Dae Won Jun, Cheng-Yuan Peng, Ming-Lun Yeh, Huy Trinh, Grace Lai-Hung Wong, Sung Eun Kim, Chien-Hung Chen, Hyunwoo Oh, Chia-Hsin Lin, Lindsey Trinh, Vincent Wai-Sun Wong, Eilleen Yoon, Sang Bong Ahn, Daniel Huang, Yong Kyun Cho, Jae Yoon Jeong, Soung Won Jeong, Hyoung Su Kim, Qing Xie, Li Liu, Mar Riveiro-Barciela, Pei-Chien Tsai, Elena Vargas Accarino, Hidenori Toyoda, Masaru Enomoto, Carmen Preda, Sebastian Marciano, Joseph Hoang, Chung-Feng Huang, Ritsuzo Kozuka, Satoshi Yasuda, Doina Istratescu, Dong-Hyun Lee, Jia-Ying Su, Yen-Tsung Huang, Jee Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Man-Fung Yuen, Adrian Gadano, Ramsey Cheung, Seng Gee Lim, Maria Buti, Ming-Lung Yu, Mindie H. Nguyen

Summary: This study showed that there was no significant difference in the incidence of HBsAg seroclearance between ETV and TDF in patients with CHB, and this rarely occurred with either regimen.

HEPATOLOGY INTERNATIONAL (2022)

Review Gastroenterology & Hepatology

A critique and systematic review of the clinical utility of hepatitis B core-related antigen

Celina Adraneda, Yong Chuan Tan, Ee Jin Yeo, Guan Sen Kew, Atefeh Khakpoor, Seng Gee Lim

Summary: This study systematically evaluated the clinical utility of hepatitis B core-related antigen (HBcrAg) in chronic hepatitis B (CHB) and found that HBcrAg has limited performance and poor correlation with HBsAg loss and antiviral therapy.

JOURNAL OF HEPATOLOGY (2023)

Review Gastroenterology & Hepatology

The scientific basis of combination therapy for chronic hepatitis B functional cure

Seng Gee Lim, Thomas F. Baumert, Carolina Boni, Ed Gane, Massimo Levrero, Anna S. Lok, Mala K. Maini, Norah A. Terrault, Fabien Zoulim

Summary: Functional cure of chronic hepatitis B (CHB), achieved through hepatitis B surface antigen (HBsAg) loss after 24 weeks off therapy, is the goal of current treatment. However, the rarity of achieving this cure with current therapy highlights the need for novel approaches. The three categories of treatment include reducing viral replication, reducing antigen load, and immunotherapies. Combination therapy of nucleos(t)ide analogues and immunotherapy shows promise in reducing HBsAg levels and inducing HBsAg loss in some patients, particularly those with low baseline HBsAg levels. Monitoring during therapy using viral and immunological biomarkers is important to predict HBsAg loss and understand its mechanisms.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2023)

Letter Gastroenterology & Hepatology

Improved basic performance of iTACT-HBcrAg assay and Using a commercial diagnostic assay requires compliance with the manufacturer's recommendations

Seng Gee Lim, Ee Jin Yeo, Celina Adraneda, Yong Chuan Tan

JOURNAL OF HEPATOLOGY (2023)

Meeting Abstract Gastroenterology & Hepatology

Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection on stable nucleos (t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study

Man-Fung Yuen, Robert Plesniak, Seng Gee Lim, Keiji Tsuji, Gheorghe Diaconescu, Adrian Gadano, Ju Hyun Kim, Tarik Asselah, Hyung Joon Yim, Jeong Heo, Giuliano Rizzardini, Harry Janssen, Corneliu Petru Popescu, Diana Petrova, Alexander Wong, Nevin Indriz, Cristina Pojoga, Yasuhito Tanaka, Denis Gusev, Ewa Janczewska, Jennifer Cremer, Robert Elston, Tamara Lukic, Lauren Maynard, Stuart Kendrick, Punam Bharania, Fiona Campbell, Melanie Paff, Dickens Theodore

JOURNAL OF HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

Long-read sequencing of HCC samples reveals complete architecture of HBV integrations and chimeric mRNA isoforms associated with oncogenes

Cameron Soulette, Lindsey May, Atefeh Khakpoor, Dong Han, Ricardo Ramirez, Narmada Balakrishnan, Nicholas Van Buuren, Ramanuj Dasgupta, Vithika Suri, Li Li, Hongmei Mo, Becket Feierbach, Jeffrey Wallin, Seng Gee Lim

JOURNAL OF HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

Randomised double-blind study of nitazoxanide for virologically suppressed HBeAg negative chronic Hepatitis B

Yong Chuan Tan, Liang Shen, Htet Htet Toe Wai Khine, Yuh Ling Amy Tay, Celina Adraneda, Jean-Francois Rossignol, Celine Rossignol, Seng Gee Lim

JOURNAL OF HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

Hepatitis B core related antigen, not as good as it seems: a critique and systematic review

Yong Chuan Tan, Celina Adraneda, Ee Jin Yeo, Guan Sen Kew, Atefeh Khakpoor, Seng Gee Lim

JOURNAL OF HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

Distribution of patients by guideline-defined disease phase and/or grey zones in B-Clear, an international multicentre clinical trial

Seng Gee Lim, Cristina Pojoga, Harry Janssen, Michio Imamura, Ewa Janczewska, Robert Plesniak, Keiji Tsuji, Corneliu Petru Popescu, Diana Petrova, Adrian Gadano, Alexander Wong, Tarik Asselah, Hyung Joon Yim, Jeong Heo, Man-Fung Yuen, Gheorghe Diaconescu, Giuliano Rizzardini, Jennifer Cremer, Robert Elston, Stuart Kendrick, Geoff Quinn, Fiona Campbell, Melanie Paff, Dickens Theodore

JOURNAL OF HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

Quantitative HBsAg (qHBsAg) as an end point to stop nucleos (t) ide analogues in chronic hepatitis B: a meta-analysis with meta-regression

Seng Gee Lim, Ada Ee Der Teo, Edwin Shih-Yen Chan, Wah Wah Phyo, David Hsing Yu Chen, Carol Anne Hargreaves

JOURNAL OF HEPATOLOGY (2022)

No Data Available